Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic Malignacies

Etablissement Français du Sang1,101 enrolled

Overview

Platelet concentrates (PCs) characteristics, such as storage duration, ABO compatibility, dose and source, may have an impact on transfusion responses and outcomes. Because of the relative scarcity of PCs the selection of a specific PC for issue to the patient remains a challenging process. Regulatory agencies do not fully address these characteristics in their recommendations for prophylactic transfusions. The aim of the study was to analyse the effect of product-related factors in a real life setting, in order to determine which ones are the most relevant when selecting PCs for patients in prophylactic conditions. Two different endpoints are studied: the corrected count increment and the platelet transfusion time intervals.

Study Type

OBSERVATIONAL

Enrollment

1,101

Conditions

Lymphoma Multiple Myeloma Lymphocytic Leukemia Hodgkin Disease

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Inpatients in the hematology department between January 2001 and December 2012 * Hematologic malignancy * At least one platelet transfusion (with platelet count ≤ 25 G/L) * Age 18 and over at time of first transfusion Exclusion Criteria: * More than one hematologic malignancy * Non-malignant haematological disorder

Outcomes

Primary Outcomes

Corrected count increment

Platelet increment corrected for platelet dose and body surface area

Time frame: 24 hours post transfusion

Secondary Outcomes

Transfusion interval

Time interval to following platelet transfusion in days

Time frame: 7 days